abstract: Do eosinophils modulate lymphocyte function? This question was studied by examining the effect of purified eosinophils (eos) on lectin-induced @entity0 lymphocyte proliferation. Intact resting or zymosan-stimulated eos or their extracts were cocultured with phytohemagglutinin-stimulated mononuclear cells in vitro and @entity3 uptake was measured at 72 hr. Zymosan-stimulated eos consistently suppressed (up to 90%) the lectin-induced proliferative response by a noncytotoxic mechanism. Freeze-thaw extracts from zymosan-stimulated eos also significantly suppressed lymphocyte proliferation to a similar degree. The amount of suppression was directly proportional to the number of eos or the amount of extract added to the lymphocyte cultures. Intact resting eos and their extracts occasionally exhibited suppressive effects (up to 40%) on lymphocyte proliferation; this suppression, however, was always less than that of activated eos or their extracts. Eos pretreated with the protein synthesis inhibitor, @entity5 , exhibited significantly less suppressive activity, suggesting that a protein was responsible in part for the reduction in proliferation. The addition of @entity2 dismutase or @entity4 to the eos-mononuclear cell cocultures did not reduce the amount of suppression observed, thus making it unlikely that active @entity1 products were involved in the mechanism of suppression. Heating extracts from stimulated eos to 80 degrees C for 30 min resulted in partial loss of suppressive activity while extensive dialysis of the extracts had no effect. The studies reported here provide evidence that a nondialyzable and heat sensitive factor(s) produced by stimulated eos may exert feedback inhibition of lymphocyte function.

title: XXXX lymphocyte-eosinophil interactions. I. Modulation of phytohemagglutinin-induced lymphocyte proliferation by eosinophils.

answer: @entity0


abstract: Clinical and experimental data have documented the ability of nontransmural @entity2 to produce abnormal Q waves on both the epicardial and body surfaces. We undertook this study to define the anatomic determinants of such Q wave development. Thirty @entity1 were studied before and after occlusion-reperfusion (26 @entity1 ) or latex embolization (four @entity1 ) of the left circumflex coronary artery. Occlusion was maintained for 60 to 240 min before reperfusion to produce nontransmural lesions of various sizes. Electrocardiographic data were registered from 84 torso electrodes by body surface mapping techniques before and 1 week after @entity3 . @entity3 size was quantitated by computer analysis of heart slices stained with @entity4 . Six @entity1 did not develop @entity3 . Of the remaining 24, 10 did and 14 did not develop significant changes in body surface Q wave duration and width. The incidence of Q wave changes was not different in @entity1 with nontransmural and those with transmural lesions. @entity3 size (expressed as a percentage of the left ventricle infarcted), the percentage of endocardium subjacent to @entity3 , the average depth of @entity0 , the percent of the four outer fifths of the ventricular wall infarcted, and the duration of occlusion were significantly (p less than .05) greater in @entity1 with than in those without Q wave changes. Logistic regression modeling demonstrated that only two anatomic parameters--percentage of left ventricle infarcted and average lesion depth--significantly and independently predicted Q wave development. A model including only these two variables accurately classified all 24 cases.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Electrocardiographic effects of experimental nontransmural XXXX .

answer: @entity2


abstract: The long-term behavior of @entity1 fiber ligament replacements was evaluated in @entity2 . In vitro assessments of both isolated @entity1 fiber prostheses and resected animal ligaments were performed. The right knee in 45 @entity2 was reconstructed. In 30 animals, only the medical collateral ligaments were replaced, but with different systems of anchorage to bone. In 15 animals, a combined replacement of medial collateral ligament and anterior cruciate ligament was performed. In the first group the animals were sacrificed three months postoperation, while in the latter group evaluation was performed one year after surgery. After one year the strength of the medial collateral ligament complex was higher than that of the normal @entity2 ligaments. The elasticity and extensibility were similar to those of the normal ligaments. No case of @entity0 or @entity0 of the medial collateral ligament replacements was seen, but four of 12 anterior cruciate replacements showed signs of @entity0 . In vitro testing showed that @entity0 is more likely to occur where movement occurs around a small radius of bending, and this may be a factor in these cases where the anterior cruciate ligament enters a bony tunnel at an acute angle. Histologic assessment showed good biocompatibility, similar to that reported by other authors. With an operative technique designed to increase the radius of bending where the @entity1 fiber enters bone, these ligament replacements have a fatigue strength and elasticity adequate for long-term survival.

title: In vivo and in vitro investigation of the long-term behavior and fatigue strength of XXXX fiber ligament replacement.

answer: @entity1


abstract: OBJECTIVE: To investigate the plasma level of @entity1 -terminal pro-brain natriuretic peptide (NT-proBNP) and related influencing factors in a community-based healthy population in Beijing area. METHODS: We measured plasma NT-proBNP level by fluoroimmunoassay between March 2012 and July 2012 from 1 034 healthy subjects (including 486 @entity0 and 548 @entity0 ). Empiric method was used to determine the reference value and influencing factors were analyzed. RESULTS: Age and gender are important factors affecting the level of NT-proBNP in healthy subjects. NT-proBNP plasma level is significantly higher in @entity0 than in @entity0 within each age strata below 75 years old, i.e. < 45, 45-54, 55-64 and 65-74 years old (P = 0.005, 0.001, 0.001, 0.011 respectively), but NT-proBNP plasma level is similar between male and female older than 75 years (P = 0.504). NT-proBNP level also increases with age irrespective of gender. Body mass index (BMI) is another independent influencing factor of NT-proBNP (P < 0.001), while estimated glomerular filtration rate is not influencing factor. The reference range of NT-proBNP is < 133 ng/L for @entity0 and < 289 ng/L for @entity0 aged < 55 years old, < 185 ng/L for @entity0 and < 333 ng/L for @entity0 aged between 55 and 64 years old, and < 465 ng/L for @entity0 and < 378 ng/L for @entity0 aged >=  75 years old. CONCLUSION: The major influencing factors of NT-proBNP level in the healthy population are age, gender and BMI. It essential to establish normal reference range of NT-proBNP according to these factors for Chinese population.

title: [Plasma XXXX -terminal pro-brain natriuretic peptide level and affecting factors in a community-based healthy Chinese population].

answer: @entity1


abstract: BACKGROUND: @entity3 is traditionally classified on the basis of the response to standard @entity2 treatment. Mutations in more than 24 genes have been associated with @entity3 in @entity0 , although the great majority of @entity2 -resistant cases have been attributed to mutations in three main genes: @entity4 , @entity6 and @entity5 . The aims of this study were to identify mutations in these genes more frequently reported as mutated and to characterize each variation using different in silico prediction algorithms in order to understand their biological functions. METHODS: We performed direct sequence analysis of exons 8 and 9 of @entity5 , 8 exons of @entity6 and 29 exons of @entity4 , including @entity6 and @entity4 intron-exon boundary sequences, as well as 700  bp of the 5' UTR from both genes in 27 @entity2 -resistant @entity0 aged between 3  months and 18  years. RESULTS: Analysis of the @entity6 gene revealed four missense mutations, one frameshift mutation and three variations in the 5' UTR. Four @entity0 presented compound heterozygosis, and four other @entity0 presented one heterozygous alteration only. @entity5 and @entity4 gene analysis did not reveal any mutations. DISCUSSION: This is the first study focusing on genetics of  SRNS in Brazilian @entity0 . Identification of mutations is important because it could  influence physicians' decision on @entity0 treatment, as @entity0 carrying mutations can  be spared the side effects of immunosuppressive therapy and ultimately could be  considered for kidney transplantation from a living donor. CONCLUSIONS: After molecular analysis of the genes more frequently reported as mutated in 27 @entity2 -resistant @entity3 @entity0 , we identified @entity6 mutations confirming the hereditary character of the @entity1 in only 14.8  % of @entity0 . Therefore, the next step is to perform a next generation sequencing based analysis of glomeluropathy-related panel of genes for the remaining @entity0 in order to search for mutations in other genes related to @entity2 -resistant @entity3 .

title: XXXX mutations account for only 15  % of @entity3 cases.

answer: @entity6


abstract: BACKGROUND: @entity3 is traditionally classified on the basis of the response to standard @entity2 treatment. Mutations in more than 24 genes have been associated with @entity3 in @entity0 , although the great majority of @entity2 -resistant cases have been attributed to mutations in three main genes: @entity4 , @entity6 and @entity5 . The aims of this study were to identify mutations in these genes more frequently reported as mutated and to characterize each variation using different in silico prediction algorithms in order to understand their biological functions. METHODS: We performed direct sequence analysis of exons 8 and 9 of @entity5 , 8 exons of @entity6 and 29 exons of @entity4 , including @entity6 and @entity4 intron-exon boundary sequences, as well as 700  bp of the 5' UTR from both genes in 27 @entity2 -resistant @entity0 aged between 3  months and 18  years. RESULTS: Analysis of the @entity6 gene revealed four missense mutations, one frameshift mutation and three variations in the 5' UTR. Four @entity0 presented compound heterozygosis, and four other @entity0 presented one heterozygous alteration only. @entity5 and @entity4 gene analysis did not reveal any mutations. DISCUSSION: This is the first study focusing on genetics of  SRNS in Brazilian @entity0 . Identification of mutations is important because it could  influence physicians' decision on @entity0 treatment, as @entity0 carrying mutations can  be spared the side effects of immunosuppressive therapy and ultimately could be  considered for kidney transplantation from a living donor. CONCLUSIONS: After molecular analysis of the genes more frequently reported as mutated in 27 @entity2 -resistant @entity3 @entity0 , we identified @entity6 mutations confirming the hereditary character of the @entity1 in only 14.8  % of @entity0 . Therefore, the next step is to perform a next generation sequencing based analysis of glomeluropathy-related panel of genes for the remaining @entity0 in order to search for mutations in other genes related to @entity2 -resistant @entity3 .

title: @entity6 mutations account for only 15  % of XXXX cases.

answer: @entity3


abstract: The effect of @entity5 on the cardiovascular @entity1 of @entity4 was investigated in a @entity0 model. Under @entity7 (400 mg/kg intraperitoneal) anesthesia, unilateral femoral venous and bilateral femoral arterial cannulae were placed for administration of drugs, for blood sampling, and for continuous qualitative monitoring of arterial blood pressure. Lead II ECG was continuously recorded and a tracheostomy performed to increase FIO2 by use of a "T-piece." Four groups of 24 to 36 @entity0 each were studied. All @entity0 received IV @entity4 2 mg/kg, within 10 seconds. Group I, the control group, received only @entity4 . Groups II and III received IV @entity5 0.2 mg/kg, or @entity5 vehicle in an equivalent volume, respectively. Five minutes after this pretreatment, groups II and III received IV @entity4 2 mg/kg. Group IV was given @entity5 , 0.2 mg/kg, 30 seconds after injection of 2 mg/kg @entity4 . A marked respiratory and @entity2 occurred in all @entity0 but was significantly worse in groups II and III. No @entity0 in the study became hypoxemic. Serious @entity3 (ventricular or @entity6 ) were noted in all groups, but the incidence was significantly higher in the group of @entity0 given @entity5 pretreatment than in the other three groups. It is concluded that IV @entity5 0.2 mg/kg given 5 minutes before administration of IV @entity4 2 mg/kg increases the incidence of serious @entity3 . Second, this increase is not solely due to increased @entity2 , because the @entity0 receiving the vehicle (group III) developed equivalent @entity2 but did not develop increased @entity3 .

title: Does XXXX really reduce the cardiotoxic effects of intravenous @entity4 ?

answer: @entity5


abstract: The effect of @entity5 on the cardiovascular @entity1 of @entity4 was investigated in a @entity0 model. Under @entity7 (400 mg/kg intraperitoneal) anesthesia, unilateral femoral venous and bilateral femoral arterial cannulae were placed for administration of drugs, for blood sampling, and for continuous qualitative monitoring of arterial blood pressure. Lead II ECG was continuously recorded and a tracheostomy performed to increase FIO2 by use of a "T-piece." Four groups of 24 to 36 @entity0 each were studied. All @entity0 received IV @entity4 2 mg/kg, within 10 seconds. Group I, the control group, received only @entity4 . Groups II and III received IV @entity5 0.2 mg/kg, or @entity5 vehicle in an equivalent volume, respectively. Five minutes after this pretreatment, groups II and III received IV @entity4 2 mg/kg. Group IV was given @entity5 , 0.2 mg/kg, 30 seconds after injection of 2 mg/kg @entity4 . A marked respiratory and @entity2 occurred in all @entity0 but was significantly worse in groups II and III. No @entity0 in the study became hypoxemic. Serious @entity3 (ventricular or @entity6 ) were noted in all groups, but the incidence was significantly higher in the group of @entity0 given @entity5 pretreatment than in the other three groups. It is concluded that IV @entity5 0.2 mg/kg given 5 minutes before administration of IV @entity4 2 mg/kg increases the incidence of serious @entity3 . Second, this increase is not solely due to increased @entity2 , because the @entity0 receiving the vehicle (group III) developed equivalent @entity2 but did not develop increased @entity3 .

title: Does @entity5 really reduce the cardiotoxic effects of intravenous XXXX ?

answer: @entity4


abstract: Interaction between baroreceptors and chemoreceptors during simultaneous activation of the reflexes was studied in eight @entity3 -anesthetized vagotomized @entity0 . The carotid sinus reflexogenic area was isolated and perfused at controlled carotid sinus pressure (CSP), @entity2 , and PCO2. Random combinations of CSP, @entity2 , and PCO2 were delivered to the carotid sinus. Results were analyzed by multiple linear regression. For the arterial pressure response, increasing @entity1 resulted in an upward shift of the baroreceptor reflex response curve and an increased slope of the linear portion of the curve. The heart rate-CSP curve was also shifted upward by @entity1 , with the effect being greatest at high levels of CSP. The respiratory frequency- @entity1 relationship had an increased slope and was shifted upward when CSP was decreased. The responses of tidal volume and ventilation (VE) depended on all three inputs. At any level of @entity2 , decreasing CSP resulted in a parallel shift of the VE- @entity1 relationship. The results indicate that there is a significant interaction between chemoreceptor and baroreceptor reflex sensitivities.

title: Interaction of carotid chemoreceptor and baroreceptor reflexes in anesthetized XXXX .

answer: @entity0


abstract: Little is known of the incidence of @entity6 ( @entity6 ) associated with facial @entity1 . To study this problem, we conducted a retrospective review of 200 consecutive admissions to the University of Michigan Medical Center Emergency Department from 1980 to 1985 for treatment of @entity2 . All @entity0 were admitted within 48 hours of injury (93% within 24 hours). Medical records were reviewed for age, sex, description, and circumstances of @entity7 ; assessment of @entity4 and anterograde @entity5 ; and associated intracranial or extracranial injuries. Seventy-three percent of the @entity0 were @entity0 (mean age, 27.8 years). Etiologies, in descending order, were road traffic accidents (52%), assaults (22%), sports (14%), falls (7%), other injuries (3%), and gunshot wounds (2%). The incidence rate of @entity6 in our study was 55%. More than 90% of the @entity3 were associated with the @entity4 of less than one hour. Risk factor analysis failed to demonstrate that an increased risk of @entity6 is associated with age, sex, or number of @entity2 . However, there was a one and one-halffold increased risk associated with @entity0 involved in automobile accidents.

title: The spectrum of closed- XXXX in facial @entity1 victims: incidence and impact.

answer: @entity3


abstract: Little is known of the incidence of @entity6 ( @entity6 ) associated with facial @entity1 . To study this problem, we conducted a retrospective review of 200 consecutive admissions to the University of Michigan Medical Center Emergency Department from 1980 to 1985 for treatment of @entity2 . All @entity0 were admitted within 48 hours of injury (93% within 24 hours). Medical records were reviewed for age, sex, description, and circumstances of @entity7 ; assessment of @entity4 and anterograde @entity5 ; and associated intracranial or extracranial injuries. Seventy-three percent of the @entity0 were @entity0 (mean age, 27.8 years). Etiologies, in descending order, were road traffic accidents (52%), assaults (22%), sports (14%), falls (7%), other injuries (3%), and gunshot wounds (2%). The incidence rate of @entity6 in our study was 55%. More than 90% of the @entity3 were associated with the @entity4 of less than one hour. Risk factor analysis failed to demonstrate that an increased risk of @entity6 is associated with age, sex, or number of @entity2 . However, there was a one and one-halffold increased risk associated with @entity0 involved in automobile accidents.

title: The spectrum of closed- @entity3 in facial XXXX victims: incidence and impact.

answer: @entity1


abstract: BACKGROUND/AIMS: Survivin, a member of the inhibitor of apoptosis protein family, is an attractive target for @entity1 therapy. We investigated the effects of @entity5 , a small molecule inhibitor of survivin expression, on the radiosensitivity of @entity0 @entity2 ( @entity2 ) cell lines and elucidated a relationship between the cellular localization of survivin and DNA double-strand break repair. METHODS: The cellular distribution of survivin was determined by Western blotting of subcellular fractions and by immunofluorescent staining in A549 @entity2 cells. Radiation-induced DNA damage was evaluated based on histone H2AX phosphorylation and foci formation. The relationship between the cellular localization of survivin and DNA double-strand break repair was analyzed by Western blotting and co-immunoprecipitations. RESULTS: @entity5 down-regulated survivin expression in @entity2 cells in a concentration- and time-dependent manner. An in vitro clonogenic survival assay revealed that @entity5 increased the sensitivity of @entity2 cells to radiation. After irradiation, we observed a rapid accumulation of survivin in the nucleus. An immunofluorescent analysis of histone x03B3;-H2AX demonstrated that the inhibition of survivin expression by @entity5 resulted in impaired DNA double-strand break repair. Co-immunoprecipitation assays using nuclear extracts revealed an interaction between survivin, @entity3 , x03B3;-H2AX, and @entity4 . Furthermore, S2056 autophosphorylation of @entity4 was reduced in survivin-depleted cells. CONCLUSIONS: These results suggested that @entity5 sensitized @entity2 cells to radiation, at least in part by inhibiting DNA repair and enhancing apoptosis via the down-regulation of survivin expression. @entity5 pretreatment inhibited @entity4 autophosphorylation at S2056. Nuclear survivin was involved in DNA double-strand break repair via interactions with members of the DNA double-strand break repair machinery.

title: The Mechanism of Radiosensitization by XXXX , a Novel Small Molecule Inhibitor of Survivin Expression, is Associated with DNA Damage Repair.

answer: @entity5


abstract: BACKGROUND: This study examined the effects of @entity3 , heart rate recovery, and physical activity on working memory in @entity0 survivors and age-matched controls. METHOD: Using a case-control design, 32 @entity1 who had received a @entity0 and completed primary treatment within the past 36-months (11 radiation only; 21 chemotherapy) and 30 age-matched @entity1 with no previous @entity2 diagnosis completed a n-back continuous performance task commonly used as an assessment of working memory. In addition, @entity3 and heart rate recovery were measured during a submaximal graded exercise test and physical activity was measured using 7-days of accelerometer monitoring. RESULTS: Breast @entity2 survivors who had received chemotherapy had poorer heart rate recovery (p   =   .010) and engaged in less physical activity than @entity1 who had received radiation only (p   =   .004) or non- @entity2 controls (p   =   .029). Cancer treatment (radiation; chemotherapy) predicted differences in reaction times on the 1-back working memory task (p   =   .029). However, more rapid heart rate recovery predicted shorter reaction times on the 1-back task in the age-matched control group (p   =   .002). All @entity1 with greater @entity3 displayed greater accuracy independent of disease status on the 1-back task (p   =   .017). No significant group differences in reaction times were observed for 2-back target trials between @entity0 survivors and controls. However, greater total physical activity predicted shorter reaction times in @entity0 survivors (radiation, chemotherapy) on the 2-back task (p   =   .014). In addition, all @entity1 who exhibited more rapid heart rate recovery demonstrated better greater accuracy regardless of disease status (p   =   .013). CONCLUSION: These findings support differences in physical activty participation, heart rate recovery, and 1- and 2-back working memory reaction times between @entity0 survivors and age-matched controls. Greater @entity3 , heart rate recovery, and physical activity were positively associated with better working memory performance across conditions.

title: Associations Between Physical Fitness Indices and Working Memory in XXXX and Age-Matched Controls.

answer: @entity0


abstract: The @entity8 are a group of disorders with wide genetic and clinical heterogeneity. Recently, mutations in the @entity9 gene, which encodes a putative @entity2 -activated @entity5 channel belonging to the Anoctamin family of proteins, were identified in five families with one of two previously identified disorders, @entity8 2L and @entity6 . We screened a candidate group of 64 @entity0 from 59 British and German kindreds and found the truncating mutation, @entity11 in exon 5 of @entity9 in 20 @entity0 , homozygously in 15 and in compound heterozygosity with other @entity9 variants in the rest. An intragenic single nucleotide polymorphism and an extragenic microsatellite marker are in linkage disequilibrium with the mutation, suggesting a founder effect in the Northern European population. We have further defined the clinical phenotype of @entity9 -associated @entity6 . @entity0 show adult onset proximal lower limb @entity1 with highly raised serum @entity3 kinase values (average 4500 IU/l) and frequent @entity4 and asymmetry of muscle involvement. Onset varies from the early 20 s to 50 s and the @entity1 is @entity7 progressive, with most @entity0 remaining ambulant for several decades. Distal presentation is much less common but a milder degree of distal lower limb @entity1 is often observed. Upper limb strength is only mildly affected and cardiac and respiratory function is normal. Females appear less frequently affected. In the North of England population we have identified eight @entity0 with @entity9 mutations, suggesting a minimum prevalence of 0.27/100,000, twice as common as @entity10 . We suggest that mutations in @entity9 represent a relatively common cause of adult onset @entity6 with high serum @entity3 kinase and that mutation screening, particularly of the common mutation @entity11 , should be an early step in the diagnostic algorithm of adult @entity8 @entity0 .

title: A founder mutation in @entity9 is a major cause of XXXX .

answer: @entity8


abstract: The @entity8 are a group of disorders with wide genetic and clinical heterogeneity. Recently, mutations in the @entity9 gene, which encodes a putative @entity2 -activated @entity5 channel belonging to the Anoctamin family of proteins, were identified in five families with one of two previously identified disorders, @entity8 2L and @entity6 . We screened a candidate group of 64 @entity0 from 59 British and German kindreds and found the truncating mutation, @entity11 in exon 5 of @entity9 in 20 @entity0 , homozygously in 15 and in compound heterozygosity with other @entity9 variants in the rest. An intragenic single nucleotide polymorphism and an extragenic microsatellite marker are in linkage disequilibrium with the mutation, suggesting a founder effect in the Northern European population. We have further defined the clinical phenotype of @entity9 -associated @entity6 . @entity0 show adult onset proximal lower limb @entity1 with highly raised serum @entity3 kinase values (average 4500 IU/l) and frequent @entity4 and asymmetry of muscle involvement. Onset varies from the early 20 s to 50 s and the @entity1 is @entity7 progressive, with most @entity0 remaining ambulant for several decades. Distal presentation is much less common but a milder degree of distal lower limb @entity1 is often observed. Upper limb strength is only mildly affected and cardiac and respiratory function is normal. Females appear less frequently affected. In the North of England population we have identified eight @entity0 with @entity9 mutations, suggesting a minimum prevalence of 0.27/100,000, twice as common as @entity10 . We suggest that mutations in @entity9 represent a relatively common cause of adult onset @entity6 with high serum @entity3 kinase and that mutation screening, particularly of the common mutation @entity11 , should be an early step in the diagnostic algorithm of adult @entity8 @entity0 .

title: A founder mutation in XXXX is a major cause of @entity8 .

answer: @entity9


abstract: OBJECTIVE: To explore the association between quality of care for surgical and @entity1 @entity0 and the racial/ethnic composition of hospitals' @entity0 . DATA SOURCE: Our primary data were surgical and @entity1 processes of care indicators from the 2012 Medicare Hospital Compare Data. We merged this data with information from the 2011 American Hospital Association Annual Survey of Hospitals. We computed the racial and ethnic composition of hospital @entity0 using 2008 data from the Healthcare Costs and Utilization Project. STUDY DESIGN: The sample included 1,198 acute care general hospitals from 11 states: AZ, CA, FL, IA, MA, @entity2 , NC, NJ, NY, WA, and WI. We compared quality across minority-serving, racially integrated, and majority-white hospitals using unconditional quantile regression models controlling for hospital and market characteristics. PRINCIPAL FINDINGS: We found quality differences between the lowest performing minority-serving, racially integrated, and majority-white hospitals. As we moved from 10th to 90th quantile, the quality differences between hospitals by @entity0 ' racial composition disappeared. In other words, the best minority-serving and racially integrated hospitals performed as well as the best majority hospitals. CONCLUSIONS: Efforts to improve quality of care for @entity0 in minority-serving and racially integrated hospitals should focus on the lowest performers.

title: The Quality of XXXX Care in Minority-Serving and Racially Integrated Hospitals.

answer: @entity1


abstract: We have retrospectively reviewed the charts of 34 acral @entity3 @entity0 ( @entity3 arising from the volar skin of the hands, feet or a subungual site) seen in the Auckland area between 1970 and 1985. These 34 @entity0 constituted 3.5 per cent of the total number of @entity0 (972) reviewed over this period. Six of the thirty-four @entity0 were either Polynesian or Maori. There were 19 @entity0 and 15 @entity0 , and the mean age of the group was 59 years. The @entity1 arose from the plantar or palmar skin in 25 @entity0 and 9 @entity0 had @entity1 . All lesions but one were pigmented. Most @entity0 with @entity1 presented with clinical stage 1, Clark's level 4 disease, while those with @entity1 presented most commonly with stage 2, Clark's level 5 disease. Treatment was wide local resection for plantar and @entity1 and amputation for @entity1 . Regional lymph node dissection was performed in 10 @entity0 with positive nodes at presentation and in 6 @entity0 who developed metachronous nodal disease. @entity0 were followed for between 1 and 16 years, and 18 @entity0 died in this period, 15 of @entity3 (mean time 34 months). @entity3 carried a worse prognosis than @entity3 arising in @entity2 .

title: Acral (volar-subungual) XXXX in Auckland, New Zealand.

answer: @entity3


abstract: PURPOSE:To observe the changes of ocular fundus and to describe the image features of optical coherence tomography (OCT) in @entity0 with laser-induced @entity4 . METHODS:Four @entity0 (4 eyes) with decreased visual acuity due to laser injury were recruited into the study between April 2002 to December 2009. All @entity0 underwent routine check-up for eyes. RESULTS:The four cases presented with different clinical characteristics from each another. In the first case, OCT showed lamella macular hole, with partially remained outer sensory retina. The signals of inner segments/outer segments (IS/OS) band and RPE band were disrupted. The choroidal band was distorted with increased reflection. Perimacular epiretinal membrane and @entity3 were also observed. The second case had a full-thickness macular hole with @entity1 surrounding the hole. The third case presented @entity5 in macula. The fourth case presented @entity2 which indicated @entity3 . CONCLUSION:There are various patterns of laser-induced @entity4 . OCT is a useful noninvasive diagnostic tool to delineate the layer, extent and configuration of the damage on retina.

title: [Image characters of optical coherence tomography in laser-induced XXXX .]

answer: @entity4


abstract: The present studies examined the patterns of circulating @entity1 (T) within 0-24 h after birth in male and female ferrets along with concomitant changes in neural aromatase activity and hypothalamic concentrations of @entity0 (E2). Plasma and brain samples were obtained 0 and 2 h (cesarean delivery) or 0, 2, 12, and 24 h (natural delivery) after birth. Plasma T levels were significantly higher in male neonates 2 h after birth than at 0 h in both cesarean-delivered (9.48 +/- 1.25 vs. 3.37 +/- 0.60 ng/ml) and naturally delivered (19.28 +/- 2.94 vs. 5.13 +/- 1.93 ng/ml) ferrets, while female neonates showed no significant changes in T over these sampling times. T levels had returned to 0 h levels by 12 h in naturally delivered males. T was significantly lower in females than in males 0, 2, and 24 h after natural delivery, whereas T levels were equivalent in males and females immediately after cesarean delivery. Male kits kept on a heating pad for 2 h after natural delivery had lower plasma T levels than males that were left with their mothers over this same period. Brain aromatase activity in anterior hypothalamus-preoptic area, @entity2 ( @entity2 ), temporal lobe, and cerebral cortex was equivalent in males and females at all postpartum ages, regardless of whether delivery occurred by cesarean section or naturally. However, in naturally delivered kits of both sexes significant elevations in aromatase activity occurred in @entity2 and temporal lobe 24 h postpartum. Finally, E2 concentrations in anterior hypothalamus-preoptic area and @entity2 were equivalent 0 and 2 h postpartum in males and females, regardless of whether they were delivered naturally or by cesarean section. The observed postnatal elevation in T may contribute to brain and behavioral sexual differentiation of male ferrets. It is unclear, however, whether such an effect of T depends on its neural aromatization to E2.

title: Effect of birth on plasma XXXX , brain aromatase activity, and hypothalamic @entity0 in male and female ferrets.

answer: @entity1


abstract: The present studies examined the patterns of circulating @entity1 (T) within 0-24 h after birth in male and female ferrets along with concomitant changes in neural aromatase activity and hypothalamic concentrations of @entity0 (E2). Plasma and brain samples were obtained 0 and 2 h (cesarean delivery) or 0, 2, 12, and 24 h (natural delivery) after birth. Plasma T levels were significantly higher in male neonates 2 h after birth than at 0 h in both cesarean-delivered (9.48 +/- 1.25 vs. 3.37 +/- 0.60 ng/ml) and naturally delivered (19.28 +/- 2.94 vs. 5.13 +/- 1.93 ng/ml) ferrets, while female neonates showed no significant changes in T over these sampling times. T levels had returned to 0 h levels by 12 h in naturally delivered males. T was significantly lower in females than in males 0, 2, and 24 h after natural delivery, whereas T levels were equivalent in males and females immediately after cesarean delivery. Male kits kept on a heating pad for 2 h after natural delivery had lower plasma T levels than males that were left with their mothers over this same period. Brain aromatase activity in anterior hypothalamus-preoptic area, @entity2 ( @entity2 ), temporal lobe, and cerebral cortex was equivalent in males and females at all postpartum ages, regardless of whether delivery occurred by cesarean section or naturally. However, in naturally delivered kits of both sexes significant elevations in aromatase activity occurred in @entity2 and temporal lobe 24 h postpartum. Finally, E2 concentrations in anterior hypothalamus-preoptic area and @entity2 were equivalent 0 and 2 h postpartum in males and females, regardless of whether they were delivered naturally or by cesarean section. The observed postnatal elevation in T may contribute to brain and behavioral sexual differentiation of male ferrets. It is unclear, however, whether such an effect of T depends on its neural aromatization to E2.

title: Effect of birth on plasma @entity1 , brain aromatase activity, and hypothalamic XXXX in male and female ferrets.

answer: @entity0


abstract: PURPOSE: We evaluated the relative risk of later grade reclassification and outcomes of @entity0 in whom high volume @entity2 develops while on active surveillance. MATERIALS AND METHODS: A prospectively maintained database was used to identify @entity0 on active surveillance between 1998 and 2013. @entity1 volume was assessed based on the number of positive cores and proportion of core involvement. The chi-square and Fisher exact tests were used for analysis as appropriate. The primary end point was the development of grade reclassification, defined as grade only and/or grade and volume at the event biopsy. RESULTS: A total of 555 @entity0 met the study inclusion criteria. Mean followup was 46 months. Overall 70 @entity0 demonstrated an increase in @entity1 volume at or after biopsy 2. Compared to those @entity0 never experiencing volume or grade reclassification, @entity3 at diagnosis was not significantly different (p=0.95), but median prostate volume was smaller in @entity0 who demonstrated volume reclassification (p <0.001). The incidence of pure volume reclassification was 6.8%, 6.1% and 7.8% at biopsy 2, 3 and 4, respectively. @entity0 with volume reclassification were more likely to experience later grade reclassification than those without at 33.3% vs 9.3%, respectively (p <0.0001). CONCLUSIONS: While @entity2 has a favorable natural history, it appears that @entity0 on active surveillance who experience volume reclassification are at substantially higher risk for grade reclassification. Thus, urologists should pay close attention to @entity1 core involvement, and monitoring should be adjusted accordingly for early volume reclassification in younger @entity0 and those in good health.

title: An Increase in Gleason 6 XXXX Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup.

answer: @entity1


abstract: PURPOSE: To investigate @entity6 and @entity2 ( @entity2 ) levels in the vitreous fluid of @entity0 with @entity1 ( @entity1 ) and to examine their correlation with @entity1 activity. METHODS: Vitreous samples from 45 eyes with @entity1 and 28 eyes with @entity3 were collected. Active @entity1 was present in 24 @entity0 and inactive @entity1 in 21 @entity0 , according to @entity5 . The @entity6 and @entity2 level of vitreous fluid samples were measured by enzyme-linked immunosorbent assay. RESULTS: Comparison revealed that mean intravitreal levels of @entity6 increased significantly in @entity4 compared with control eyes (13.55 ng/mL vs. 1.57 ng/mL, P < 0.001). The mean @entity2 concentrations in the vitreous fluid of @entity0 with @entity1 were also higher than those in nondiabetic controls, with the values being 723.21 pg/mL and 20.81 pg/mL, respectively (P < 0.001). In addition, vitreous concentrations of @entity6 and @entity2 were significantly higher in active @entity1 than in eyes with inactive @entity1 (P = 0.016 and P = 0.008, respectively). Furthermore, a significant positive correlation was detected between @entity6 and @entity2 levels in the vitreous. CONCLUSION: Intravitreous levels of @entity6 and @entity2 in @entity0 with @entity1 are increased and correlated mutually. @entity6 may be an important player in the development of @entity1 and its activity in vitreous fluid can be biomarker of @entity1 .

title: CORRELATION OF INCREASED INTRAVITREOUS @entity6 WITH XXXX IN PROLIFERATIVE DIABETIC RETINOPATHY.

answer: @entity2


abstract: PURPOSE: To investigate @entity6 and @entity2 ( @entity2 ) levels in the vitreous fluid of @entity0 with @entity1 ( @entity1 ) and to examine their correlation with @entity1 activity. METHODS: Vitreous samples from 45 eyes with @entity1 and 28 eyes with @entity3 were collected. Active @entity1 was present in 24 @entity0 and inactive @entity1 in 21 @entity0 , according to @entity5 . The @entity6 and @entity2 level of vitreous fluid samples were measured by enzyme-linked immunosorbent assay. RESULTS: Comparison revealed that mean intravitreal levels of @entity6 increased significantly in @entity4 compared with control eyes (13.55 ng/mL vs. 1.57 ng/mL, P < 0.001). The mean @entity2 concentrations in the vitreous fluid of @entity0 with @entity1 were also higher than those in nondiabetic controls, with the values being 723.21 pg/mL and 20.81 pg/mL, respectively (P < 0.001). In addition, vitreous concentrations of @entity6 and @entity2 were significantly higher in active @entity1 than in eyes with inactive @entity1 (P = 0.016 and P = 0.008, respectively). Furthermore, a significant positive correlation was detected between @entity6 and @entity2 levels in the vitreous. CONCLUSION: Intravitreous levels of @entity6 and @entity2 in @entity0 with @entity1 are increased and correlated mutually. @entity6 may be an important player in the development of @entity1 and its activity in vitreous fluid can be biomarker of @entity1 .

title: CORRELATION OF INCREASED INTRAVITREOUS XXXX WITH @entity2 IN PROLIFERATIVE DIABETIC RETINOPATHY.

answer: @entity6


abstract: BACKGROUND: Decompensated @entity2 ( @entity2 ) is associated with unacceptable morbidity and mortality risks. Recent implantable technology advancements allow frequent filling pressure monitoring and provide insight into @entity2 pathophysiology and a new tool for @entity2 management. METHODS: The CHAMPION trial is a prospective, multicenter, randomized, single-blind clinical trial testing the hypothesis that @entity2 management guided by frequently assessed @entity1 pressures is superior to traditional methods. A total of 550 subjects with New York Heart Association (NYHA) functional class III @entity2 were enrolled at 64 sites in the United States. All subjects received the CardioMEMS @entity2 sensor as a permanent @entity1 implant and were randomized to the treatment or the control group before discharge. The treatment group received traditional @entity2 management guided by hemodynamic information from the sensor. The control group received traditional @entity2 disease management. Safety endpoints include freedom from device/system-related complications and freedom from @entity2 at 6 months. The efficacy endpoint is a reduction in the rate of @entity2 -related hospitalizations in the treatment group versus the control group at 6 months. CONCLUSIONS: The CHAMPION trial will investigate the safety and clinical efficacy of the CardioMEMS hemodynamic monitoring system and may establish this management strategy as a new paradigm for the medical management of @entity0 with symptomatic @entity2 .

title: CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless XXXX pressure monitoring system.

answer: @entity1


abstract: UNASSIGNED: The essential oil from different parts of Datura metel L. were extracted using hydrodistillation and GC-MS was used to analyse the essential oil. The main components of flowers were @entity1 (23.61%) and @entity3 (15.84%). The main components of leaves were @entity1 (18.84%) and @entity4 (18.71%). @entity1 (39.45%) and @entity4 (31.32%) were the major components of petioles. @entity2 (30.60%) and @entity5 (21.56%) were the major components of seeds. The major ingredient of roots was @entity2 (52.61%). The main ingredients of the stems were @entity2 (38.38%) and @entity5 (17.38%). All the different parts of essential oil were screened for @entity0 . The roots and stems showed the inhibitory effects against HepG-2 with IC50 levels of 613.88 and 341.12  mg/L. The leaves and roots showed the inhibitory effects against HeLa with IC50 levels of 267.76 and 348.35  mg/L. All the six parts have inhibitory effects against SGC-7901 cell lines.

title: Chemical composition and XXXX of the essential oil from different parts of Datura metel L.

answer: @entity0


abstract: AIM: Incisional @entity2 represent a late onset complication of any type of laparotomy, with a relatively high incidence, and reported in 2% to 11% of all laparotomies. MATERIAL AND METHODS: We performed a prospective longitudinal study that included a total number of 102 @entity0 . The following parameters were monitored: @entity0 history clinical findings, time of hospitalization, laboratory test results, types of surgery. Intra-abdominal pressure variations were measured using a specialized kit. RESULTS: Obesity was present in 69 of the @entity0 (67.64%). Mesh plasty was most frequently used (80.39%). The inset of the mesh was performed in onlay position (40.19%), retromuscular (29.98%) or complete defect substitution (11.76%). The correlation between the type of abdominal wall plasty, variations on the Borg @entity3 scal and likewise the correlation between the VAS (visual analogue scale) pain scale and the abdominal wall plasty procedures proved to be highly statistically significant: p< 0.001. Furthermore, the intra-abdominal pressure varied with the type of abdominoplasty carried out, reviewing the tension free principle. The most important parameter was the intra-abdominal pressure recorded at the end of the abdominoplasty, which showed significant correlations with the tension free plasties (retromuscular mesh and substitution mesh). CONCLUSIONS: The tension free methods, reflected by the intra-abdominal pressure variation, were associated with a lower degree of @entity3 , @entity1 and less hospitalization time. KEY WORDS: Borg scale, Incisional @entity2 , Intra-abdominal pressure, Onlay, Visual analogue scale.

title: The intraabdominal pressure A real indicator of the tension free principle during anterior wall repair procedure after incisional XXXX .

answer: @entity2


abstract: BACKGROUND: Reliable blood and urine markers for transitional cell @entity2 ( @entity7 ) do not currently exist. The aim of this prospective study was the serological and immunohistochemical evaluation of CA19.9 and @entity4 in @entity7 and to assess the correlation with different @entity7 stages. @entity0 AND METHODS: CA19.9 and @entity4 levels were prospectively determined in samples from 231 @entity0 with @entity7 suspected @entity5 , before transurethral @entity1 resection. Additionally, these serum parameters were determined in 11 @entity0 with initial metastatic @entity7 . Immunohistochemical analysis on CA19.9 and @entity4 was performed in 83 @entity0 . RESULTS: Neither CA19.9 nor @entity4 levels were significantly elevated in @entity7 @entity0 . @entity0 with muscle-invasive @entity7 showed significantly higher levels of @entity4 (p = 0.008) and CA19.9 (p<0.001) compared to those with superficial @entity7 . Significantly higher levels were also evident with increasing grade of @entity1 . Metastatic @entity7 showed significantly elevated CA19.9 levels compared to muscle invasive @entity7 as well as locally advanced ( @entity6 /pT4/pN+) compared to localized @entity7 (pT2/pN0). Immunohistochemical staining revealed a strong correlation between CA19.9 serum levels and staining intensity. CONCLUSION: @entity4 and CA19.9 are not useful markers in primary diagnosis of @entity7 . However, in instances of elevated @entity4 and CA19.9 levels where @entity3 has been excluded, evidence of @entity7 should be sought. If elevated @entity4 and CA19.9 are present in @entity7 , serum levels correlate with @entity1 invasion and grade of @entity1 .

title: CA19.9 and @entity4 in transitional cell XXXX : serological and immunohistochemical findings.

answer: @entity2


abstract: BACKGROUND: Reliable blood and urine markers for transitional cell @entity2 ( @entity7 ) do not currently exist. The aim of this prospective study was the serological and immunohistochemical evaluation of CA19.9 and @entity4 in @entity7 and to assess the correlation with different @entity7 stages. @entity0 AND METHODS: CA19.9 and @entity4 levels were prospectively determined in samples from 231 @entity0 with @entity7 suspected @entity5 , before transurethral @entity1 resection. Additionally, these serum parameters were determined in 11 @entity0 with initial metastatic @entity7 . Immunohistochemical analysis on CA19.9 and @entity4 was performed in 83 @entity0 . RESULTS: Neither CA19.9 nor @entity4 levels were significantly elevated in @entity7 @entity0 . @entity0 with muscle-invasive @entity7 showed significantly higher levels of @entity4 (p = 0.008) and CA19.9 (p<0.001) compared to those with superficial @entity7 . Significantly higher levels were also evident with increasing grade of @entity1 . Metastatic @entity7 showed significantly elevated CA19.9 levels compared to muscle invasive @entity7 as well as locally advanced ( @entity6 /pT4/pN+) compared to localized @entity7 (pT2/pN0). Immunohistochemical staining revealed a strong correlation between CA19.9 serum levels and staining intensity. CONCLUSION: @entity4 and CA19.9 are not useful markers in primary diagnosis of @entity7 . However, in instances of elevated @entity4 and CA19.9 levels where @entity3 has been excluded, evidence of @entity7 should be sought. If elevated @entity4 and CA19.9 are present in @entity7 , serum levels correlate with @entity1 invasion and grade of @entity1 .

title: CA19.9 and XXXX in transitional cell @entity2 : serological and immunohistochemical findings.

answer: @entity4


abstract: PURPOSE: To report the radiological and clinical results of revision @entity3 ( @entity3 ) with femoral impaction bone grafting (IBG). METHODS: 4 @entity0 and 9 @entity0 (15 hips) aged 38 to 84 years underwent revision @entity3 with femoral IBG using Elite plus stems for aseptic loosening or @entity2 . RESULTS: The mean follow-up duration was 7.7 years. The Harris hip score improved from 61.7 to 83.7. There was no @entity1 in 11 hips and slight @entity1 in 4. The mean subsidence was 5.7 mm. The mean change of alignment was 1.2 degrees. There was no radiological evidence of stem loosening. One stem was revised due to a peri-prosthetic fracture. Cortical healing was noted in 11 hips, and trabecular incorporation in 10. CONCLUSION: Although intra- and post-operative complications were not uncommon, femoral IBG is a safe procedure in carefully selected @entity0 and offers good medium-term results.

title: Revision XXXX with femoral impaction bone grafting.

answer: @entity3


abstract: UNASSIGNED: This study was designed to investigate whether @entity9 inhibitors (PPI, V-ATPase blocker) could increase the effect of cytotoxic agents in @entity3 (EOC). Expression of V-ATPase protein was evaluated in @entity0 with EOC using immunohistochemistry, and @entity0 survival was compared based on expression of V-ATPase mRNA from a TCGA data set. In vitro, EOC cell lines were treated with chemotherapeutic agents with or without V-ATPase siRNA or PPI ( @entity8 ) pretreatment. Cell survival and apoptosis was assessed using @entity4 assay and ELISA, respectively. In vivo experiments were performed to confirm the synergistic effect with @entity8 and @entity6 on @entity1 growth in orthotopic and @entity0 -derived xenograft (PDX) @entity2 models. Expression of V-ATPase protein in @entity3 tissues was observed in 44 @entity0 (44/59, 74.6%). Higher expression of V-ATPase mRNA was associated with poorer overall survival in TCGA data. Inhibition of V-ATPase by siRNA or @entity8 significantly increased @entity5 or apoptosis to @entity6 in chemoresistant (HeyA8-MDR, SKOV3-TR) and @entity7 cells (ES-2, RMG-1), but not in chemosensitive cells (HeyA8, SKOV3ip1). Moreover, the combination of @entity8 and @entity6 significantly decreased the total @entity1 weight compared with @entity6 alone in a chemoresistant EOC animal model and a PDX model of @entity7 . However, this finding was not observed in chemosensitive EOC animal models. These results show that @entity8 pretreatment can increase the effect of chemotherapeutic agents in chemoresistant EOC and @entity7 via @entity1 microenvironment.

title: XXXX inhibitors enhance the effects of cytotoxic agents in @entity3 .

answer: @entity9


abstract: UNASSIGNED: This study was designed to investigate whether @entity9 inhibitors (PPI, V-ATPase blocker) could increase the effect of cytotoxic agents in @entity3 (EOC). Expression of V-ATPase protein was evaluated in @entity0 with EOC using immunohistochemistry, and @entity0 survival was compared based on expression of V-ATPase mRNA from a TCGA data set. In vitro, EOC cell lines were treated with chemotherapeutic agents with or without V-ATPase siRNA or PPI ( @entity8 ) pretreatment. Cell survival and apoptosis was assessed using @entity4 assay and ELISA, respectively. In vivo experiments were performed to confirm the synergistic effect with @entity8 and @entity6 on @entity1 growth in orthotopic and @entity0 -derived xenograft (PDX) @entity2 models. Expression of V-ATPase protein in @entity3 tissues was observed in 44 @entity0 (44/59, 74.6%). Higher expression of V-ATPase mRNA was associated with poorer overall survival in TCGA data. Inhibition of V-ATPase by siRNA or @entity8 significantly increased @entity5 or apoptosis to @entity6 in chemoresistant (HeyA8-MDR, SKOV3-TR) and @entity7 cells (ES-2, RMG-1), but not in chemosensitive cells (HeyA8, SKOV3ip1). Moreover, the combination of @entity8 and @entity6 significantly decreased the total @entity1 weight compared with @entity6 alone in a chemoresistant EOC animal model and a PDX model of @entity7 . However, this finding was not observed in chemosensitive EOC animal models. These results show that @entity8 pretreatment can increase the effect of chemotherapeutic agents in chemoresistant EOC and @entity7 via @entity1 microenvironment.

title: @entity9 inhibitors enhance the effects of cytotoxic agents in XXXX .

answer: @entity3


abstract: BACKGROUND: Long-term effects of restrictive mitral annuloplasty (RMA), especially on hemodynamics and left ventricular (LV) function in @entity0 with functional @entity3 ( @entity3 ), have not been fully investigated. METHODS AND RESULTS: From 1999 to 2008, 44 @entity0 with @entity5 and functional @entity3 underwent RMA with stringent downsizing of the mitral annulus. Serial echocardiography was performed to evaluate LV function (reverse remodeling), estimated @entity4 (PAP) and mitral valve geometry at baseline and at discharge, and annually thereafter. Cardiac catheterization was performed at baseline, and at discharge to evaluate acute hemodynamic change. There were 3 early deaths, and the 5-year survival rate was 78    8%. In 41 survivors the clinical symptoms, stratified according to New York Heart Association class, significantly improved after surgery. Postoperative cardiac catheterization showed significant unloading for left ventricle, as well as improvement in LV systolic function. Serial echocardiography showed that improvements in LV function and systolic PAP were sustained in the majority of @entity0 . Multivariate Cox regression analysis identified preoperative @entity1 (systolic PAP>60 mm Hg) as the significant predictor for postoperative adverse @entity2 . CONCLUSIONS: RMA for functional @entity3 resulted in sustained improvement of hemodynamics and LV function over time. Additional studies are needed to define the negative impact of preoperative @entity1 in @entity0 with this condition.

title: Restrictive mitral annuloplasty for functional XXXX : acute hemodynamics and serial echocardiography.

answer: @entity3


abstract: PURPOSE: To conduct ophthalmic, behavioral, electrophysiological, and genetic testing on two related Gordon setters presented for @entity0 and compare findings with those of nine related and unrelated Gordon setters. METHODS: All @entity1 underwent comprehensive ophthalmic examination. Maze testing was conducted under different light intensities. Rod and cone function was assessed electroretinographically. DNA samples were screened for five @entity1 retinal disease gene mutations. RESULTS: Ophthalmic examination was unremarkable in all @entity1 . There was no notable difference between day blind @entity1 and the reference population in scotopic and mesopic maze tests. Day blind @entity1 performed worse in the photopic maze with slower course completion time and more obstacle collisions. Electroretinography revealed extinguished cone function in day blind @entity1 and depressed rod responses in all but two reference @entity1 . One reference population @entity1 presented with @entity0 1 year after initial examination. Mutations that cause @entity4 (in @entity6 ) and @entity5 (in @entity7 and @entity8 ) were not detected in any @entity1 tested, although five reference @entity1 were carriers of the mutation in C2orf71 that causes rod-cone degeneration 4 (rcd4) in Gordon setters and in polski owczarek nizinny @entity1 . CONCLUSIONS: This report describes a novel @entity3 in related Gordon setters that has clinical signs and vision testing results consistent with @entity4 but electroretinographic results suggestive of @entity5 . The majority of Gordon setters in this study had low rod responses on electroretinography but it is unclear whether this was indicative of @entity2 or normal for the breed. Longer-term observation of affected individuals is warranted.

title: Novel XXXX in related Gordon setters: a clinical, behavioral, electrophysiological, and genetic investigation.

answer: @entity3


abstract: INTRODUCTION AND BACKGROUND: Surgical techniques for the treatment of @entity1 continue to evolve; however, there is still no accepted criterion standard. Until recently, the Alder Hey supraregional craniofacial department's experience was principally with combined wide-vertex suturectomy and biparietal barrel stave osteotomies. AIMS AND OBJECTIVES: To determine whether the technique of wide-vertex suturectomy and biparietal barrel stave osteotomies improves the cephalic index (CI) in scaphocephalic @entity0 and determine whether age at surgery influences outcomes. @entity0 AND METHODS: A literature review was undertaken to confirm recognized outcome measures. @entity0 who had surgery between 2000 and 2006 were enrolled in the audit. Prospective database review allowed preoperative and postoperative data collection at 6 weeks, 6 months, and 2 years. Statistical analysis was performed with Statview V.5.0.1 (Adept Scientific, Letchworth, UK). RESULTS: Of 73 @entity0 referred to the unit with @entity1 , 66 underwent surgery. Of these 66 @entity0 , 54 were @entity0 and 12 @entity0 . Mean age at surgery was 11.1 months, with a mode of 6 months and a median of 8 months (range, 4-56 mo). Mean change in CI from the preoperative value was significant at 6 weeks (P < 0.0001) and 6 months (P < 0.0001) after surgery. Early correction of @entity1 ( <= 9 mo) was associated with a normal CI at 6 weeks after surgery (P = 0.03). CONCLUSIONS: Wide-vertex suturectomy with biparietal barrel stave osteotomies are effective at increasing the CI in @entity0 with @entity1 . Early correction is associated with an improved CI in the short term, but long-term outcomes are unclear and require further follow-up studies.

title: Treatment of XXXX with combined vertex craniectomy and bilateral microbarrel staving.

answer: @entity1


abstract: The aim of this paper is to describe neurofeedback (NFB) treatment in @entity2 ( @entity2 ) @entity0 . There is no specific cure for @entity2 and therapeutic guidelines are directed to improve the quality of life of @entity0 with @entity2 by reducing the symptoms and by increasing their functioning. Neurofeedback is a computerized method based on tracking electrical activity of the brain (EEG) and giving a feedback about it. The method has been developed in neurophysiological labs of scientific institutes in USA and has been used very successfully for over last 20 years. It has proven its efficacy in practise, but also in scientific and clinical research. During 2010 and 2011 neurofeedback treatment was administered to 10 @entity0 (N=10, 7 males and 3 females) age range 4 to 7 years which have been diagnosed as @entity2 (highly functional) with an unspecific impairment of speech development and trouble communicating. An evaluation of treatment was done according to estimation of changes in functioning (parents, teachers and therapists' ratings and all other experts that were monitoring the @entity0 before, during and after the treatment) and tracking of changes in electrophysiology. The results have shown most changes in behaviour (less aggressive, more cooperation, better communication), @entity1 . According to the assessment of parents, teachers, therapists and other experts all @entity0 have accomplished a certain degree of improvement in the level of daily functioning. Our experiences in usage of neurofeedback in @entity2 ( @entity2 ) @entity0 confirmed previous data that this method can be applied to this category of @entity0 .

title: Neurofeedback application in the treatment of XXXX ( @entity2 ).

answer: @entity2


abstract: The aim of this paper is to describe neurofeedback (NFB) treatment in @entity2 ( @entity2 ) @entity0 . There is no specific cure for @entity2 and therapeutic guidelines are directed to improve the quality of life of @entity0 with @entity2 by reducing the symptoms and by increasing their functioning. Neurofeedback is a computerized method based on tracking electrical activity of the brain (EEG) and giving a feedback about it. The method has been developed in neurophysiological labs of scientific institutes in USA and has been used very successfully for over last 20 years. It has proven its efficacy in practise, but also in scientific and clinical research. During 2010 and 2011 neurofeedback treatment was administered to 10 @entity0 (N=10, 7 males and 3 females) age range 4 to 7 years which have been diagnosed as @entity2 (highly functional) with an unspecific impairment of speech development and trouble communicating. An evaluation of treatment was done according to estimation of changes in functioning (parents, teachers and therapists' ratings and all other experts that were monitoring the @entity0 before, during and after the treatment) and tracking of changes in electrophysiology. The results have shown most changes in behaviour (less aggressive, more cooperation, better communication), @entity1 . According to the assessment of parents, teachers, therapists and other experts all @entity0 have accomplished a certain degree of improvement in the level of daily functioning. Our experiences in usage of neurofeedback in @entity2 ( @entity2 ) @entity0 confirmed previous data that this method can be applied to this category of @entity0 .

title: Neurofeedback application in the treatment of @entity2 ( XXXX ).

answer: @entity2


abstract: PURPOSE: Previous studies have suggested that postmenopausal @entity1 with @entity0 who present with wild-type @entity3 may actually have similar or superior recurrence-free survival outcomes when given @entity2 in place of aromatase inhibitors (AIs). The present study established a @entity3 multiple-genotype-based model to determine the optimal endocrine therapy for @entity1 harboring wild-type @entity3 . METHODS: We created a Markov model to determine whether @entity2 or AIs maximized 5-year disease-free survival (DFS) for extensive metabolizer (EM) @entity1 using annual hazard ratio (HR) data from the @entity4 -98 trial. We then replicated the model by evaluating 9-year event-free survival (EFS) using HR data from the ATAC trial. In addition, we employed two-way sensitivity analyses to explore the impact of HR of decreased-metabolizer (DM) and its frequency on survival by studying a range of estimates. RESULTS: The 5-year DFS of @entity2 -treated EM @entity1 was 83.3%, which is similar to that of genotypically unselected @entity1 who received an AI (83.7%). In the validation study, we further demonstrated that the 9-year EFS of @entity2 -treated EM @entity1 was 81.4%, which is higher than that of genotypically unselected @entity1 receiving @entity2 (78.4%) and similar to that of @entity1 receiving an AI (83.2%). Two-way sensitivity analyses demonstrated the robustness of the results. CONCLUSIONS: Our modeling analyses indicate that, among EM @entity1 , the DFS/EFS outcome of @entity1 receiving @entity2 is similar to that of @entity1 receiving an AI. Further prospective clinical trials are needed to evaluate the value of the @entity3 genotype in the selection of endocrine therapy.

title: Tailoring adjuvant endocrine therapy for XXXX : a @entity3 multiple-genotype-based modeling analysis and validation.

answer: @entity0


abstract: PURPOSE: Previous studies have suggested that postmenopausal @entity1 with @entity0 who present with wild-type @entity3 may actually have similar or superior recurrence-free survival outcomes when given @entity2 in place of aromatase inhibitors (AIs). The present study established a @entity3 multiple-genotype-based model to determine the optimal endocrine therapy for @entity1 harboring wild-type @entity3 . METHODS: We created a Markov model to determine whether @entity2 or AIs maximized 5-year disease-free survival (DFS) for extensive metabolizer (EM) @entity1 using annual hazard ratio (HR) data from the @entity4 -98 trial. We then replicated the model by evaluating 9-year event-free survival (EFS) using HR data from the ATAC trial. In addition, we employed two-way sensitivity analyses to explore the impact of HR of decreased-metabolizer (DM) and its frequency on survival by studying a range of estimates. RESULTS: The 5-year DFS of @entity2 -treated EM @entity1 was 83.3%, which is similar to that of genotypically unselected @entity1 who received an AI (83.7%). In the validation study, we further demonstrated that the 9-year EFS of @entity2 -treated EM @entity1 was 81.4%, which is higher than that of genotypically unselected @entity1 receiving @entity2 (78.4%) and similar to that of @entity1 receiving an AI (83.2%). Two-way sensitivity analyses demonstrated the robustness of the results. CONCLUSIONS: Our modeling analyses indicate that, among EM @entity1 , the DFS/EFS outcome of @entity1 receiving @entity2 is similar to that of @entity1 receiving an AI. Further prospective clinical trials are needed to evaluate the value of the @entity3 genotype in the selection of endocrine therapy.

title: Tailoring adjuvant endocrine therapy for @entity0 : a XXXX multiple-genotype-based modeling analysis and validation.

answer: @entity3


abstract: UNASSIGNED: One important task in translational @entity1 research is the search for new prognostic biomarkers to improve survival prognosis for @entity0 . The use of high-throughput technologies allows simultaneous measurement of genome-wide gene expression or other genomic data for all @entity0 in a clinical trial. Penalized likelihood methods such as lasso regression can be applied to such high-dimensional data, where the number of (genomic) covariables is usually much larger than the sample size. There is a connection between the lasso and the Bayesian regression model with independent Laplace priors on the regression parameters, and understanding this connection has been useful for understanding the properties of lasso estimates in linear models (e.g. Park and Casella, ). In this paper, we study the lasso in the frequentist and Bayesian frameworks in the context of @entity2 models. For the Bayesian lasso we extend the approach by Lee et  al. (). In particular, we impose the lasso penalty only on the genome features, but not on relevant clinical covariates, to allow the mandatory inclusion of important established factors. We investigate the models in high- and low-dimensional simulation settings and in an application to @entity3 .

title: Nonidentical twins: Comparison of frequentist and Bayesian lasso for XXXX models.

answer: @entity2


abstract: The clinical and pathological associations of @entity3 in @entity0 who presented to the Royal Adelaide Hospital between January 1, 1968 and February 29, 1984 were reviewed retrospectively. Cases of @entity13 were excluded. Of 59 @entity0 with @entity3 , clear associations with diseases were identified in 42 (71%) @entity0 . These were @entity8 (seven cases), @entity11 (12 cases), @entity6 (three cases), @entity9 (four cases), @entity14 (three cases), other @entity7 (four cases), drug @entity2 (four cases) and @entity1 (five cases). Ten @entity0 had multiple associations and five other @entity0 presented without any clearly defined cause for @entity12 . Three of these latter @entity0 presented with an @entity5 , showed @entity10 and had abnormal results of liver function tests. These cases may represent the entity that is labeled "idiopathic @entity3 ". Two other @entity0 abused @entity4 . @entity12 were categorized morphologically as microgranulomas, macrogranulomas and lipogranulomas according to their size, organization and the presence of fat droplets. Microgranulomas were associated with diseases of short duration and less @entity11 . The presence of @entity12 did not confer any prognostic implication over and above that of the associated disease.

title: XXXX : a 15-year experience in the Royal Adelaide Hospital.

answer: @entity3


abstract: OBJECTIVE: @entity5 is a 5-alpha reductase inhibitor used to treat @entity3 . @entity5 lowers @entity4 levels, which may lead to delays in the diagnosis and treatment of @entity1 ( @entity1 ). This study investigated @entity0 who underwent prostate biopsy (PBx) while receiving @entity5 to investigate whether this agent affects the diagnosis and treatment of @entity1 . @entity0 AND METHODS: PBx was performed on six @entity0 receiving @entity5 for > 3 months at our medical institutions between January 2010 and June 2013. No @entity0 underwent PBx before @entity5 administration. We performed PBx both for @entity0 with high initial @entity4 levels and for those with elevated @entity4 levels with or without initial @entity4 decline after @entity5 administration. We also investigated clinicopathological findings. RESULTS: Mean age at the start of administration was 69.5    5.9 years (range, 59-77 years), mean duration of administration was 14.1    7.4 months (range, 4.0-23.5 months), mean prostate volume at the start of administration was 70.4    30.7 ml (range, 18.8-104.6 ml), and mean @entity4 level at the start of administration was 7.7    3.3 ng/ml (range, 4.9-14.2 ng/ml). @entity4 density was 0.098    0.045 ng/ml/cm3 (range, 0.042-0.181 ng/ml/cm3), and @entity4 level at PBx was 5.4    2.7 ng/ml (range, 2.5-10.7 ng/ml). We detected three @entity1 @entity0 , and clinical stage in each case was cT1cN0M0. Radical retropubic prostatectomy was performed in two cases, and @entity2 -deprivation therapy was performed in one case. CONCLUSION: All @entity1 were detected in the early clinical stage. No delays in detection or treatment of @entity1 were seen in any cases. Careful observation of @entity4 levels is simple and useful for detecting @entity1 in @entity0 under @entity5 administration.

title: [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN @entity0 RECEIVING XXXX FOR BENIGN PROSTATIC HYPERPLASIA].

answer: @entity5


abstract: OBJECTIVE: @entity5 is a 5-alpha reductase inhibitor used to treat @entity3 . @entity5 lowers @entity4 levels, which may lead to delays in the diagnosis and treatment of @entity1 ( @entity1 ). This study investigated @entity0 who underwent prostate biopsy (PBx) while receiving @entity5 to investigate whether this agent affects the diagnosis and treatment of @entity1 . @entity0 AND METHODS: PBx was performed on six @entity0 receiving @entity5 for > 3 months at our medical institutions between January 2010 and June 2013. No @entity0 underwent PBx before @entity5 administration. We performed PBx both for @entity0 with high initial @entity4 levels and for those with elevated @entity4 levels with or without initial @entity4 decline after @entity5 administration. We also investigated clinicopathological findings. RESULTS: Mean age at the start of administration was 69.5    5.9 years (range, 59-77 years), mean duration of administration was 14.1    7.4 months (range, 4.0-23.5 months), mean prostate volume at the start of administration was 70.4    30.7 ml (range, 18.8-104.6 ml), and mean @entity4 level at the start of administration was 7.7    3.3 ng/ml (range, 4.9-14.2 ng/ml). @entity4 density was 0.098    0.045 ng/ml/cm3 (range, 0.042-0.181 ng/ml/cm3), and @entity4 level at PBx was 5.4    2.7 ng/ml (range, 2.5-10.7 ng/ml). We detected three @entity1 @entity0 , and clinical stage in each case was cT1cN0M0. Radical retropubic prostatectomy was performed in two cases, and @entity2 -deprivation therapy was performed in one case. CONCLUSION: All @entity1 were detected in the early clinical stage. No delays in detection or treatment of @entity1 were seen in any cases. Careful observation of @entity4 levels is simple and useful for detecting @entity1 in @entity0 under @entity5 administration.

title: [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN XXXX RECEIVING @entity5 FOR BENIGN PROSTATIC HYPERPLASIA].

answer: @entity0


abstract: The @entity3 ( @entity3 ) is suggested to play a pivotal role in @entity1 ; however, the dissociation pattern of functional connectivity of @entity3 subsystems remains uncharacterized in this disease. In this study, resting-state fMRI data were acquired from 55 @entity1 @entity0 and 53 matched healthy controls. @entity3 connectivity was estimated from time courses of independent components. The lateral @entity3 exhibited decreased connectivity with the unimodal sensorimotor cortex but increased connectivity with the heteromodal association areas in schizophrenics. The increased connectivity between the lateral @entity3 and right control network was significantly correlated with negative and anergia factor scores in the @entity1 @entity0 . The anterior and posterior DMNs exhibited increased and decreased connectivity with the right control and lateral visual networks, respectively, in schizophrenics. The altered @entity3 connectivity may underlie the @entity2 , delusions, thought disturbances, and negative symptoms involved in @entity1 . Furthermore, @entity3 connectivity patterns could be used to differentiate @entity0 from controls with 76.9% accuracy. These findings may shed new light on the distinct role of @entity3 subsystems in @entity1 , thereby furthering our understanding of the pathophysiology of @entity1 . Elucidating key disease-related @entity3 subsystems is critical for identifying treatment targets and aiding in the clinical diagnosis and development of treatment strategies.

title: Evidence of a dissociation pattern in default mode subnetwork functional connectivity in XXXX .

answer: @entity1


abstract: Right ventricular volume measurements and hemodynamic studies were performed in 20 @entity0 after total correction of @entity1 . There were 6 @entity0 with an extracardiac conduit and Hancock xenograft (G-1), 8 with an outflow tract patch (G-2) and 6 without or with a minimal right ventriculotomy and repair of pulmonary valve (G-3). The age at the time of operation was over 3 years in each @entity0 and averaged 5 +/- 2 (mean +/- SD) years. Right ventricular systolic pressure averaged 81 +/- 22, 55 +/- 22 and 58 +/- 30 mmHg in @entity5 , respectively. Right ventriculography showed no contraction of the right ventricular free wall at the @entity2 to the conduit and poor contraction around the @entity2 in G-1. The right ventricular enddiastolic volume index (RVEDVI) was 114 +/- 31, 155 +/- 57 and 115 +/- 28 ml/m2 in @entity5 , respectively. The right ventricular ejection fraction (RVEF) was 0.42 +/- 0.11 in G-1, 0.53 +/- 0.04 in G-2 (p less than 0.05, vs G-1) and 0.57 +/- 0.04 in G-3 (p less than 0.02, vs G-1). @entity3 was evident in 17 @entity0 , and RVEDVI correlated well with degrees of @entity4 . Fourteen @entity0 in G-2 and G-3 were divided into G-A and G-B to evaluate right ventricular function with or without pressure overloading of the right ventricle. G-A consisted of 7 @entity0 with a right ventricular systolic pressure of more than 50 mmHg (74 +/- 26) and G-B of 7 @entity0 with a value less than 50 mmHg (39 +/- 4). There was no difference in RVEDVI and RVEF between G-A and G-B. RVEF was significantly lower in G-1 than G-A (p less than 0.02) and G-B (p less than 0.05). These results suggested that an extracardiac conduit with Hancock xenograft reduced the contraction of the right ventricular free wall and induced a depressed right ventricular pump function in @entity0 with a high right ventricular pressure.

title: Right ventricular function after extracardiac conduit repair for XXXX . A comparison among surgical approaches.

answer: @entity1


abstract: OBJECTIVE: The aim of this study was to evaluate the effect of topical application of @entity1 over implant surface, placed immediately to the extraction, throughout histological and histomorphometric analysis of peri-implant tissue. MATERIAL AND METHODS: Six American foxhound @entity0 were used in the study. Mandibular premolar distal roots were extracted. Twenty-four immediate conical C1 implants (MIS, Barlev, Israel) were randomly assigned to the distal site on each site of the mandible in three groups: (Group CI) 12 @entity3 implants alone; (Test Group @entity4 ) 12 @entity3 implants supplemented with @entity1 . Prior to implanting, test implants ( @entity4 ) were submerged in @entity1 10% solution. No treatment was applied at control implants (CI). After 12  weeks, animals were sacrificed. Block sections were obtained and processed for mineralized ground sectioning. Bone-to-implant contact (Total BIC and BIC%), new bone formation (NBF), interthread bone (ITB), and histological linear measurements (HLM) were analyzed. RESULTS: At 12  weeks, all implants were clinically stable and histologically osseointegrated. BIC evaluation showed Total BIC mean and SD values for @entity4 (48.96      2.14), CI (44.56      1.75) (P  <  0.05), BIC% @entity4 (43.59      0.98), and CI (42.67      9.26) (P  >  0.05). For interthread bone formation, values were as follows: @entity4 (15.21      3.87), CI (14.79      1.45) (P  >  0.05), no statistically differences. Regarding peri-implant new bone formation, no statistically differences could be found between the two groups @entity4 (31.87      1.23), CI (27.18      2.38) (P  >  0.05). For linear measurements, test group ( @entity4 ) showed statistically significant less @entity2 (CBL) @entity4 (0.37      0.12)*, CI (1.26      0.8) (P  <  0.05), and @entity1 implants showed less lingual junctional epithelium @entity4 (1.58      0.43)*, CI (2.18      0.48) (P  <  0.05). No differences were observed in the buccal mucosa. CONCLUSION: With the limitation of animal studies, topical application of @entity1 on dental implants could reduce crestal @entity2 and increase 10% more bone-to-implant contact at 12-week follow-up period.

title: Topical applications of XXXX on implant surface for bone-to-implant contact enhance: a pilot study in @entity0 part II.

answer: @entity1


abstract: OBJECTIVE: The aim of this study was to evaluate the effect of topical application of @entity1 over implant surface, placed immediately to the extraction, throughout histological and histomorphometric analysis of peri-implant tissue. MATERIAL AND METHODS: Six American foxhound @entity0 were used in the study. Mandibular premolar distal roots were extracted. Twenty-four immediate conical C1 implants (MIS, Barlev, Israel) were randomly assigned to the distal site on each site of the mandible in three groups: (Group CI) 12 @entity3 implants alone; (Test Group @entity4 ) 12 @entity3 implants supplemented with @entity1 . Prior to implanting, test implants ( @entity4 ) were submerged in @entity1 10% solution. No treatment was applied at control implants (CI). After 12  weeks, animals were sacrificed. Block sections were obtained and processed for mineralized ground sectioning. Bone-to-implant contact (Total BIC and BIC%), new bone formation (NBF), interthread bone (ITB), and histological linear measurements (HLM) were analyzed. RESULTS: At 12  weeks, all implants were clinically stable and histologically osseointegrated. BIC evaluation showed Total BIC mean and SD values for @entity4 (48.96      2.14), CI (44.56      1.75) (P  <  0.05), BIC% @entity4 (43.59      0.98), and CI (42.67      9.26) (P  >  0.05). For interthread bone formation, values were as follows: @entity4 (15.21      3.87), CI (14.79      1.45) (P  >  0.05), no statistically differences. Regarding peri-implant new bone formation, no statistically differences could be found between the two groups @entity4 (31.87      1.23), CI (27.18      2.38) (P  >  0.05). For linear measurements, test group ( @entity4 ) showed statistically significant less @entity2 (CBL) @entity4 (0.37      0.12)*, CI (1.26      0.8) (P  <  0.05), and @entity1 implants showed less lingual junctional epithelium @entity4 (1.58      0.43)*, CI (2.18      0.48) (P  <  0.05). No differences were observed in the buccal mucosa. CONCLUSION: With the limitation of animal studies, topical application of @entity1 on dental implants could reduce crestal @entity2 and increase 10% more bone-to-implant contact at 12-week follow-up period.

title: Topical applications of @entity1 on implant surface for bone-to-implant contact enhance: a pilot study in XXXX part II.

answer: @entity0


abstract: INTRODUCTION: Proto-oncogene survivin is a member of the inhibitor of apoptosis (IAP) family of proteins. The presence of serous antibodies against survivin in @entity0 with @entity2 has been previously reported; however, there are few reports regarding the pathophysiological relationship between survivin and @entity2 . We herein investigated the expression and function of survivin in SSc @entity0 . METHODS: We performed immunohistochemistry analyses to determine the expression of @entity5 , cIAP and survivin in @entity1 from @entity0 with SSc and non-SSc. The expression levels of survivin in peripheral blood mononuclear cells (PBMCs) obtained from SSc @entity0 and healthy controls were evaluated using RT-PCR and flow cytometry. Additionally, the function of survivin was verified with overexpression experiments using monocyte-derived dendritic cells (Mo-DCs). RESULTS: The expression patterns of both @entity5 and cIAP were similar, while only the survivin expression differed between the SSc and non-SSc @entity1 . Survivin-overexpressing cells were detected in the SSc dermis frequently. The positive rate of survivin in SSc dermis (64.3  %, 9/14) was higher than that in non-SSc dermis (11.2  %, 1/9). Furthermore, survivin(+) cells expressed @entity3 , one of the DC markers. Real-time PCR and FACS analyses revealed that the survivin-WT (wild type) expression levels in PBMCs, in particular @entity4 (+) monocytes, from SSc @entity0 were higher than that from healthy controls. Additionally, the overexpression experiments showed that survivin-WT-overexpressing @entity3 (+) Mo-DCs have the characteristics of promoting cell cycle progression and decreasing apoptotic cells. CONCLUSIONS: These findings suggest that dermal survivin(+) @entity3 (+) cell infiltration may be a potential biomarker of SSc @entity1 . PBMCs and monocytes from SSc @entity0 also overexpressed survivin; therefore, dermal survivin(+) DC may be derived from peripheral blood monocytes. Additionally, survivin may be involved in dermal @entity3 (+) DC proliferation through cell cycle activation and resistance to apoptosis. Survivin may be an important molecule for the pathogenesis of SSc.

title: @entity3 (+) survivin(+) dendritic cell infiltration in dermal lesions of XXXX .

answer: @entity2


abstract: INTRODUCTION: Proto-oncogene survivin is a member of the inhibitor of apoptosis (IAP) family of proteins. The presence of serous antibodies against survivin in @entity0 with @entity2 has been previously reported; however, there are few reports regarding the pathophysiological relationship between survivin and @entity2 . We herein investigated the expression and function of survivin in SSc @entity0 . METHODS: We performed immunohistochemistry analyses to determine the expression of @entity5 , cIAP and survivin in @entity1 from @entity0 with SSc and non-SSc. The expression levels of survivin in peripheral blood mononuclear cells (PBMCs) obtained from SSc @entity0 and healthy controls were evaluated using RT-PCR and flow cytometry. Additionally, the function of survivin was verified with overexpression experiments using monocyte-derived dendritic cells (Mo-DCs). RESULTS: The expression patterns of both @entity5 and cIAP were similar, while only the survivin expression differed between the SSc and non-SSc @entity1 . Survivin-overexpressing cells were detected in the SSc dermis frequently. The positive rate of survivin in SSc dermis (64.3  %, 9/14) was higher than that in non-SSc dermis (11.2  %, 1/9). Furthermore, survivin(+) cells expressed @entity3 , one of the DC markers. Real-time PCR and FACS analyses revealed that the survivin-WT (wild type) expression levels in PBMCs, in particular @entity4 (+) monocytes, from SSc @entity0 were higher than that from healthy controls. Additionally, the overexpression experiments showed that survivin-WT-overexpressing @entity3 (+) Mo-DCs have the characteristics of promoting cell cycle progression and decreasing apoptotic cells. CONCLUSIONS: These findings suggest that dermal survivin(+) @entity3 (+) cell infiltration may be a potential biomarker of SSc @entity1 . PBMCs and monocytes from SSc @entity0 also overexpressed survivin; therefore, dermal survivin(+) DC may be derived from peripheral blood monocytes. Additionally, survivin may be involved in dermal @entity3 (+) DC proliferation through cell cycle activation and resistance to apoptosis. Survivin may be an important molecule for the pathogenesis of SSc.

title: XXXX (+) survivin(+) dendritic cell infiltration in dermal lesions of @entity2 .

answer: @entity3


abstract: Free @entity5 (FFA), @entity11 (DG), and water content were measured in the right and left cerebral hemispheres of @entity1 with @entity6 cryogenically induced to the right cerebral hemisphere. The effect of @entity2 pretreatment was also studied. Twenty-four hours after lesion, maximal @entity0 was attained concomitant with an accumulation of FFA (8.5-fold) and DG (2.9-fold). @entity4 ( @entity9 ), primarily @entity8 , increased greatly in both lipid pools. In the contralateral hemisphere, only DG levels increased, especially those containing @entity10 and @entity7 , which increased by almost 50%. By 48 h, FFA had decreased 60%, whereas DG had attained sham levels. These changes occurred prior to @entity0 resolution. @entity2 decreased the degree of @entity0 and the accumulation of @entity9 -containing DG by 30% in both hemispheres. There was a complete inhibition of FFA and @entity3 accumulation in the lesioned side. These results suggest that @entity2 : (1) inhibits phospholipases A2 that, in turn, decrease membrane phospholipid breakdown; and (2) has a limited effect on the enzymatic systems involved in @entity9 -DG accumulation. Hence, in experimentally induced @entity6 , @entity9 -containing DG, rather than FFA, may be related closely to the spreading of @entity0 fluid.

title: @entity2 effect on free fatty acid and diacylglycerol accumulation during experimentally induced XXXX .

answer: @entity6


abstract: Free @entity5 (FFA), @entity11 (DG), and water content were measured in the right and left cerebral hemispheres of @entity1 with @entity6 cryogenically induced to the right cerebral hemisphere. The effect of @entity2 pretreatment was also studied. Twenty-four hours after lesion, maximal @entity0 was attained concomitant with an accumulation of FFA (8.5-fold) and DG (2.9-fold). @entity4 ( @entity9 ), primarily @entity8 , increased greatly in both lipid pools. In the contralateral hemisphere, only DG levels increased, especially those containing @entity10 and @entity7 , which increased by almost 50%. By 48 h, FFA had decreased 60%, whereas DG had attained sham levels. These changes occurred prior to @entity0 resolution. @entity2 decreased the degree of @entity0 and the accumulation of @entity9 -containing DG by 30% in both hemispheres. There was a complete inhibition of FFA and @entity3 accumulation in the lesioned side. These results suggest that @entity2 : (1) inhibits phospholipases A2 that, in turn, decrease membrane phospholipid breakdown; and (2) has a limited effect on the enzymatic systems involved in @entity9 -DG accumulation. Hence, in experimentally induced @entity6 , @entity9 -containing DG, rather than FFA, may be related closely to the spreading of @entity0 fluid.

title: XXXX effect on free fatty acid and diacylglycerol accumulation during experimentally induced @entity6 .

answer: @entity2


abstract: We present our 12-year experience with surgical treatment of @entity4 of the thoracic aorta in a high-risk @entity0 population. Of 52 @entity0 with @entity4 , 36 @entity0 , aged 19 to 80 years, had operation. In 24 of the 36, there were three or more associated major disease processes, such as chronic @entity8 , @entity3 @entity1 , @entity6 , @entity2 , @entity7 , and @entity5 . Eight @entity0 with acute type A (ascending aorta) and seven with acute type B (descending aorta) @entity4 had emergency repair, with survival in four and seven, respectively. All @entity0 with chronic type A or B @entity4 had elective repair, and all @entity0 with acute or chronic type @entity4 had surgical treatment. Four @entity0 with acute type A and two with acute type B @entity4 had elective operation, with survival in three and one, respectively. Nine @entity0 with chronic type A and six with chronic type B @entity4 had elective operation, and all survived. Twelve @entity0 with chronic type B @entity4 did not have operation, and all were alive at early follow-up. Mortality for @entity0 having acute type @entity4 requiring emergency operation was greater than that after elective repair of acute or chronic type @entity4 . Short-term survival for chronic type B @entity4 was similar whether the @entity0 was treated medically or surgically.

title: Repair of XXXX of the thoracic aorta: 12-year experience in a high-risk population.

answer: @entity4


abstract: @entity1 has been described for the most part in adults. ORL and @entity3 are encountered in @entity0 . In neonates, only @entity4 have been reported. In their report, the authors describes the first cases of @entity1 due to @entity5 in premature @entity0 with @entity2 . Three cases are described in which this bacteria has been isolated in bronchial secretions and in the culture of the nasotracheal tube. Clinical and biological features were not specific. Only orosomucoid serum level was increased. A favourable outcome was obtained by macrolides. Epidemiological survey permitted the isolation of @entity5 in one of the nurse who had taken care of the neonates. Otherwise, these infections occurs in immunologically compromised hosts. @entity6 appears most likely as an auspicious factor.

title: [ XXXX in neonatal pulmonary infectious pathology].

answer: @entity5


abstract: BACKGROUND: The efficacy of @entity3 ( @entity5 ) varies in the treatment of @entity4 . OBJECTIVE: We sought to identify an indicator from routine pretreatment tests to predict @entity5 efficacy in the treatment of @entity4 . METHODS: In a retrospective analysis of 77 psoriatic @entity0 , the correlation between @entity5 efficacy and pretreatment routine test results was analyzed with Spearman correlation. The potential risks were further evaluated with a linear regression model. Receiver operating characteristic analysis was performed to examine the effectiveness of serum total @entity2 (tCa) to predict the effect of @entity5 on @entity4 . The highest Youden index was used to determine the cutoff point, with which the positive and negative predictive values were calculated. Synergistic effects of @entity5 and @entity2 on keratinocyte growth and @entity4 -like @entity1 model were also investigated. RESULTS: The pretreatment tCa level exhibited the closest association with @entity5 efficacy. The relative @entity4 improvement with tCa was 61.07% (95% confidence interval, 42.85-79.29; P  <  .001) and better improvements were observed in @entity0 with higher tCa (r  =  0.588; P  <  .002). @entity5 inhibited keratinocyte growth, which was enhanced synergistically by @entity2 . In a @entity4 -like @entity1 model, @entity5 strongly inhibited epidermis proliferation in the high- @entity2 group. LIMITATIONS: One limitation of our study is the relatively small sample size. CONCLUSION: Pretreatment tCa level has the highest correlation with @entity5 efficacy, which might be useful  in  predicting beneficial treatment results in @entity4 . Larger studies are required to confirm our findings.

title: Can pretreatment serum @entity2 level predict the efficacy of XXXX in the treatment of severe @entity4 ?

answer: @entity3


abstract: BACKGROUND: The efficacy of @entity3 ( @entity5 ) varies in the treatment of @entity4 . OBJECTIVE: We sought to identify an indicator from routine pretreatment tests to predict @entity5 efficacy in the treatment of @entity4 . METHODS: In a retrospective analysis of 77 psoriatic @entity0 , the correlation between @entity5 efficacy and pretreatment routine test results was analyzed with Spearman correlation. The potential risks were further evaluated with a linear regression model. Receiver operating characteristic analysis was performed to examine the effectiveness of serum total @entity2 (tCa) to predict the effect of @entity5 on @entity4 . The highest Youden index was used to determine the cutoff point, with which the positive and negative predictive values were calculated. Synergistic effects of @entity5 and @entity2 on keratinocyte growth and @entity4 -like @entity1 model were also investigated. RESULTS: The pretreatment tCa level exhibited the closest association with @entity5 efficacy. The relative @entity4 improvement with tCa was 61.07% (95% confidence interval, 42.85-79.29; P  <  .001) and better improvements were observed in @entity0 with higher tCa (r  =  0.588; P  <  .002). @entity5 inhibited keratinocyte growth, which was enhanced synergistically by @entity2 . In a @entity4 -like @entity1 model, @entity5 strongly inhibited epidermis proliferation in the high- @entity2 group. LIMITATIONS: One limitation of our study is the relatively small sample size. CONCLUSION: Pretreatment tCa level has the highest correlation with @entity5 efficacy, which might be useful  in  predicting beneficial treatment results in @entity4 . Larger studies are required to confirm our findings.

title: Can pretreatment serum @entity2 level predict the efficacy of @entity3 in the treatment of severe XXXX ?

answer: @entity4


abstract: BACKGROUND: The efficacy of @entity3 ( @entity5 ) varies in the treatment of @entity4 . OBJECTIVE: We sought to identify an indicator from routine pretreatment tests to predict @entity5 efficacy in the treatment of @entity4 . METHODS: In a retrospective analysis of 77 psoriatic @entity0 , the correlation between @entity5 efficacy and pretreatment routine test results was analyzed with Spearman correlation. The potential risks were further evaluated with a linear regression model. Receiver operating characteristic analysis was performed to examine the effectiveness of serum total @entity2 (tCa) to predict the effect of @entity5 on @entity4 . The highest Youden index was used to determine the cutoff point, with which the positive and negative predictive values were calculated. Synergistic effects of @entity5 and @entity2 on keratinocyte growth and @entity4 -like @entity1 model were also investigated. RESULTS: The pretreatment tCa level exhibited the closest association with @entity5 efficacy. The relative @entity4 improvement with tCa was 61.07% (95% confidence interval, 42.85-79.29; P  <  .001) and better improvements were observed in @entity0 with higher tCa (r  =  0.588; P  <  .002). @entity5 inhibited keratinocyte growth, which was enhanced synergistically by @entity2 . In a @entity4 -like @entity1 model, @entity5 strongly inhibited epidermis proliferation in the high- @entity2 group. LIMITATIONS: One limitation of our study is the relatively small sample size. CONCLUSION: Pretreatment tCa level has the highest correlation with @entity5 efficacy, which might be useful  in  predicting beneficial treatment results in @entity4 . Larger studies are required to confirm our findings.

title: Can pretreatment serum XXXX level predict the efficacy of @entity3 in the treatment of severe @entity4 ?

answer: @entity2


abstract: AIMS: Current smokers in the general population have a lower 2 h plasma @entity2 after an oral @entity2 tolerance test (OGTT) and a higher HbA1c than non-smokers, but the relationships between OGTT/HbA1c and smoking status have not been addressed in pregnancy. We analysed glycaemic measurements in @entity0 with @entity1 in relation to smoking status. METHODS: We performed a review of the prospectively collected database of the @entity1 . We included @entity0 with @entity1 and a singleton pregnancy who delivered between 1986 and 2006. Bivariate and multivariate analyses were used to evaluate @entity0 characteristics in relation to smoking status. RESULTS: A total of 2361 @entity0 met the inclusion criteria: 556 (23.5%) were active smokers, 266 (11.3%) quit during pregnancy and 1539 (65.2%) were non-smokers. Most baseline characteristics were similar across groups. Diagnostic OGTT was performed at a gestational age of [median (25th, 75(th) centiles)] 29 weeks (26, 33). @entity0 who smoked at the beginning of pregnancy had a higher 1-h plasma @entity2 than non-smokers [11.8 (11, 12.7), 11.6 (11, 12.6) and 11.5 (10.8, 12.5) mmol/l, for active smokers, those who quit during pregnancy and non-smokers, respectively, P < 0.001] and a lower 3-h plasma @entity2 [7.3 (5.9, 8.4), 7.6 (6.4, 8.7) and 8.0 (6.8, 9.0) mmol/l, respectively, P < 0.001]. HbA1c was higher in @entity0 who smoked at the beginning of pregnancy. Multiple regression analysis confirmed the independent association of smoking status with HbA1c and OGTT plasma @entity2 . CONCLUSIONS: In @entity0 with @entity1 who smoke at the beginning of pregnancy, the shape of the OGTT is consistent with accelerated @entity2 absorption, and @entity3 c is higher than expected for glycaemic values.

title: Smoking affects the oral @entity2 tolerance test profile and the relationship between @entity2 and XXXX .

answer: @entity1